888-969-2592
Kalkine 0
countryflagCA

Resverlogix Corp.

Healthcare CA RVX

0.05CAD
-(-%)

Last update at 2025-05-08T13:30:00Z

Day Range

0.050.05
LowHigh

52 Week Range

0.040.10
LowHigh

Fundamentals

  • Previous Close 0.05
  • Market Cap18.00M
  • Volume0
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-4.16900M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-0.06

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-12-31 2023-04-30 2022-12-31 2022-04-30 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2023-04-30 2022-12-31 2022-04-30 2021-12-31
Income before tax -16.72600M -3.59200M -3.59200M -24.75900M -24.75900M
Minority interest - - - - -
Net income -16.74100M -3.61000M -3.61000M -24.77100M -24.77100M
Selling general administrative 2.77M 6.94M 6.94M 11.12M 11.12M
Selling and marketing expenses - - - 6.69M 6.69M
Gross profit - - - - -
Reconciled depreciation 0.72M 1.01M 1.01M 1.11M 1.11M
Ebit - -12.74900M -12.74900M -15.97300M -15.97300M
Ebitda - -11.74200M -11.74200M -14.86700M -14.86700M
Depreciation and amortization - 1.01M 1.01M 1.11M 1.11M
Non operating income net other - - - - -
Operating income -6.20700M -12.74900M -12.74900M -15.97300M -15.97300M
Other operating expenses - 12.71M 12.71M 15.85M 15.85M
Interest expense 1.83M 1.63M 1.63M 0.73M 0.73M
Tax provision 0.01M 0.02M 0.02M 0.01M 0.01M
Interest income - 9.15M 9.15M 8.75M 8.75M
Net interest income -1.83700M -1.66900M -1.66900M -0.85300M -0.85300M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - 0.02M 0.02M 0.01M 0.01M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 6.21M 12.71M 12.71M 15.85M 15.85M
Cost of revenue - - - - -
Total other income expense net -8.68200M 9.16M 9.16M -8.78600M -8.78600M
Discontinued operations - - - - -
Net income from continuing ops -16.74100M -3.61000M -3.61000M -24.77100M -24.77100M
Net income applicable to common shares - -3.61000M -3.61000M -24.77100M -24.77100M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2023-04-30 2022-12-31 2022-04-30 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2023-04-30 2022-12-31 2022-04-30 2021-12-31
Total assets 6.52M 8.12M 8.12M 9.98M 9.98M
Intangible assets 2.36M 2.21M 2.21M 3.43M 3.43M
Earning assets - - - - -
Other current assets 0.00600M 0.00800M 0.00800M 0.02M 0.02M
Total liab 80.99M 67.40M 67.40M 69.85M 69.85M
Total stockholder equity -74.47400M -59.28100M -59.28100M -59.87000M -59.87000M
Deferred long term liab - - - - -
Other current liab 0.58M 2.15M 2.15M 2.12M 1.74M
Common stock - 331.42M 331.42M 326.88M 326.88M
Capital stock 333.72M 331.42M 331.42M 326.88M 326.88M
Retained earnings -462.42700M -445.68600M -445.68600M -442.07600M -442.07600M
Other liab - - - 1.29M 1.29M
Good will - - - - -
Other assets - 2.60M 2.60M 2.56M 2.56M
Cash 0.00500M 0.04M 0.04M 0.00600M 0.00600M
Cash and equivalents - - - - -
Total current liabilities 26.86M 22.73M 22.73M 17.42M 17.42M
Current deferred revenue - - - - 0.38M
Net debt 6.70M 6.45M 6.45M 7.03M 7.03M
Short term debt - 6.49M 6.49M 6.60M 6.60M
Short long term debt 6.71M 6.05M 6.05M 5.97M 5.97M
Short long term debt total - 6.49M 6.49M 7.04M 7.04M
Other stockholder equity - 54.98M 54.98M 55.32M 55.32M
Property plant equipment - 0.43M 0.43M 1.04M 1.04M
Total current assets 0.52M 2.89M 2.89M 2.95M 2.95M
Long term investments - - - - -
Net tangible assets - - - -63.29800M -63.29800M
Short term investments - - - - -
Net receivables - 0.32M 0.32M 0.31M 0.31M
Long term debt - - - - -
Inventory 0.30M 2.37M 2.37M 2.45M 2.45M
Accounts payable 14.53M 14.10M 14.10M 8.70M 8.70M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 3.64M 2.60M 2.60M 2.56M 2.56M
Deferred long term asset charges - - - - -
Non current assets total 6.00M 5.23M 5.23M 7.03M 7.03M
Capital lease obligations 0.04M 0.44M 0.44M 1.07M 1.07M
Long term debt total - 0.00000M 0.00000M 0.44M 0.44M
Breakdown 2023-12-31 2023-04-30 2022-12-31 2022-04-30 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2023-04-30 2022-12-31 2022-04-30 2021-12-31
Investments -0.51600M -0.47300M -0.47300M -0.83300M -0.83300M
Change to liabilities - -0.10200M -0.10200M 3.94M 3.94M
Total cashflows from investing activities - -0.47300M -0.47300M -0.83300M -0.83300M
Net borrowings - -0.55300M -0.55300M 5.21M 5.21M
Total cash from financing activities 3.09M 4.06M 4.06M 8.81M 8.81M
Change to operating activities - - - 0.78M 0.78M
Net income -16.74100M -3.61000M -3.61000M -24.77100M -24.77100M
Change in cash -0.03500M 0.03M 0.03M -0.08100M -0.08100M
Begin period cash flow 0.04M 0.00600M 0.00600M 0.09M 0.09M
End period cash flow 0.00500M 0.04M 0.04M 0.00600M 0.00600M
Total cash from operating activities -2.61300M -3.54100M -3.54100M -8.02400M -8.02400M
Issuance of capital stock 0.28M 4.61M 4.61M 4.02M 4.02M
Depreciation 0.72M 1.01M 1.01M 1.11M 1.11M
Other cashflows from investing activities - -0.02300M -0.02300M 0.04M 0.04M
Dividends paid - - - 0.00000M 0.00000M
Change to inventory 0.00000M -0.00800M -0.00800M -0.07200M -0.07200M
Change to account receivables - - - - -
Sale purchase of stock - 4.70M 4.70M 4.02M 4.02M
Other cashflows from financing activities - 0.45M 0.45M 5.66M 5.66M
Change to netincome - - - 10.70M 10.70M
Capital expenditures 0.45M 0.45M 0.45M 0.88M 0.88M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.61M 4.74M 4.74M 4.64M 4.64M
Stock based compensation 1.25M 2.39M 2.39M 2.62M 2.62M
Other non cash items 1.57M -8.08300M -8.08300M 8.36M 8.36M
Free cash flow -3.06100M -3.99100M -3.99100M -8.90100M -8.90100M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (CAD) Price (CAD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
RVX
Resverlogix Corp.		 - -% 0.05 - - - - -2.7969
FRX
Fennec Pharmaceuticals Inc		 0.49 5.73% 9.04 58.90 212.77 3.27 57.98 2.14 15.89
MDNA
Medicenna Therapeutics Corp		 0.06 6.00% 1.06 - 204.08 - 6.92 -6.1093
EPRX
Eupraxia Pharmaceuticals Inc		 0.10 1.88% 5.42 - - - 7.62 -3.8823
ONC
Oncolytics Biotech Inc		 - -% 0.72 - - - 6.21 -2.4457

Reports Covered

Stock Research & News

View All

Profile

Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. The company's lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, low high-density lipoprotein cholesterol, recent acute coronary syndrome, and post COVID-19 conditions. It has a partnership with Eversana Life Science Services, LLC to support the commercialization of apabetalone for COVID-19 in the United States and Canada; and developing cardiovascular and pulmonary arterial hypertension indications. The company is headquartered in Calgary, Canada.

Resverlogix Corp.

4820 Richard Road SW, Calgary, AB, Canada, T3E 6L1

Key Executives

Name Title Year Born
Mr. Donald J. McCaffrey Co-Founder, Chairman, Pres, CEO & Sec. NA
Mr. Aaron Bradley Cann C.A., CPA, CA, CPA, CBV Chief Financial Officer NA
Dr. Ewelina Kulikowski Ph.D. Chief Scientific Officer NA
Dr. Jan O. Johansson M.D., Ph.D. Sr. VP of Medical Affairs NA
Dr. Michael Sweeney M.D. Sr. VP of Clinical Devel. 1961
Sarah Zapotichny Director of Investor Relations & Corp. Communications NA
Mr. Aaron Bradley Cann C.A., CPA, CBV Chief Financial Officer NA
Dr. Michael Sweeney M.D. Senior Vice President of Clinical Development 1961
Mr. Donald J. McCaffrey Co-Founder, Chairman, President, CEO & Secretary NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.